Advertising in the Indian Journal of Pediatrics: Rates, Ad Sizes, and How to Book IJP Ads for Your Pharmaceutical Brand in India

Most pharmaceutical marketing teams we speak with have already heard of the Indian Journal of Pediatrics, but very few have actually looked at what it costs to advertise there — and when they do, the numbers tend to surprise them in both directions. The reach is broader than most expect; the rate card is more accessible than the prestige of the publication might suggest. What a lot of people miss is that IJP is not simply a prestigious academic title — it is a direct, monthly pipeline into the consulting rooms of practicing pediatricians across India and South East Asia, which makes it one of the most precisely targeted print advertisement vehicles available to any pharmaceutical company operating in the child health space.

Why Is the Indian Journal of Pediatrics the Top Choice for Pediatric Pharmaceutical Advertising?

There is a reason that pharmaceutical companies — both domestic and multinational — have been placing print advertisements in the Indian Journal of Pediatrics for decades; the journal has been in continuous publication for over 92 years, which means the brand equity it carries among pediatric practitioners is genuinely difficult to replicate through any newer media channel. Founded under the Dr. K.C. Chaudhuri Foundation and currently published by Springer Nature, IJP occupies a position in the Indian pediatric medical community that goes well beyond simple readership numbers. It is the journal that pediatricians trust for clinical guidance, which is precisely the associative environment that pharmaceutical brand promotion benefits from most.

What we tell our clients at SmartAds when they are evaluating media options for pediatric product launches is this: context matters as much as reach. A full page ad placed in a peer-reviewed journal that a doctor reads for continuing medical education carries a fundamentally different weight than the same creative running in a general health magazine. The Indian Journal of Pediatrics is indexed in SCOPUS, Medline, PubMed, EMBASE, and the Science Citation Index Expanded (SCIE), which signals to readers — and by extension to advertisers — that the editorial content surrounding their advertisement meets the highest standards of scientific scrutiny. That association is what pharmaceutical companies are really paying for when they book space in IJP, and it is something that digital banner advertising simply cannot replicate.

On top of that, the Indian Academy of Pediatrics connection gives IJP an institutional legitimacy that most standalone journals lack. The IAP has a membership base running into tens of thousands of practicing pediatricians across India, a significant proportion of whom engage with IJP as their primary peer-reviewed resource; this creates a readership that is not casual or aspirational but professionally motivated. Our experience shows that pharmaceutical brands promoting neonatal pediatrics advertising campaigns or child nutrition products consistently report stronger recall among target audience doctors when the campaign includes IJP placements compared to campaigns that rely entirely on digital channels.

What Are the Advertising Rates and Ad Sizes Available in the Indian Journal of Pediatrics?

Frankly speaking, IJP advertising rates are one of the most frequently searched but least clearly published pieces of information in the Indian medical journal advertising space, which is why we want to address this directly rather than deflect to a "contact us" response. Based on the current rate card available through the journal's official booking channels and our own agency experience placing ads in IJP, the pricing for a full page ad in a standard inside position works out to somewhere in the ballpark of ₹40,000 to ₹55,000 per insertion for a non-bleed format; a bleed ad, which extends to the trim edge of the page, typically carries a premium of roughly 10 to 15 percent over the non-bleed rate. These figures represent the IJP advertising cost for 2025 and should be treated as indicative benchmarks rather than fixed prices, since the journal's official rate card is periodically revised.

Cover positions command significantly higher premiums, as one would expect from any high-visibility print advertisement. The back cover ad — which is consistently the most sought-after position in any monthly publication — is priced at roughly two to two-and-a-half times the standard full page rate, working out to somewhere between ₹85,000 and ₹1,10,000 depending on the insertion period and whether any special issue adjacency is involved. The inside front cover and inside back cover positions sit at a middle tier, typically priced somewhere between ₹65,000 and ₹85,000 per insertion; these positions are particularly valuable because they are the first and last editorial environments a reader encounters when opening the journal, which means dwell time on those pages tends to be meaningfully higher than on deep inner pages. A half page ad in a standard inside position is priced at roughly 55 to 60 percent of the full page rate, which makes it an efficient entry point for brands that want IJP presence without committing to full-page spend across multiple issues.

The double spread ad — two facing full pages — is available in IJP and is occasionally used by larger pharmaceutical companies for major product launches or brand anniversary campaigns; this format is priced at roughly 1.8 to 2 times the single full page rate rather than a strict doubling, which actually makes it one of the better value formats when cost-per-square-centimetre is calculated. Ad insertions — loose inserts placed within the bound journal — are also available and are priced separately from display advertising, typically working out to a rate that factors in both the insertion fee and the print production cost of the insert itself. For brands considering multiple insertions across the 12 annual issues that IJP publishes, there is a discount structure in place that we have seen work out to savings of roughly 15 to 20 percent on the per-issue rate when a full-year commitment is made upfront.

What Ad Positions Offer the Highest Visibility in IJP — Cover Page vs. Inner Page?

Position selection in any monthly publication is a decision that most brands underinvest in thinking about, and medical journal advertising is no exception. The back cover ad in IJP functions almost like outdoor advertising in the sense that it is visible even when the journal is sitting on a desk or in a waiting room; pediatricians who receive the journal at their clinic address report that the back cover is often the first thing visible when the journal arrives in its wrapper, which gives that position an organic impression count that goes beyond the formal readership figure. We have seen pharmaceutical brands use the back cover position specifically for product awareness campaigns where the goal is recognition rather than detailed messaging, and the results in terms of recall scores have consistently validated that premium.

The inside front cover is the position we most often recommend to clients who want a balance between visibility and cost efficiency; it is the first full-page advertisement a reader encounters after opening the journal, which means it benefits from the same attentiveness that readers bring to the editorial content on the facing page. Cover page advertising — meaning the front cover itself — is not typically available for commercial advertising in peer-reviewed journals like IJP, as editorial integrity policies maintained by Springer Nature and the Dr. K.C. Chaudhuri Foundation reserve the front cover for scientific imagery and volume information. This is worth knowing before a client builds a campaign plan around a cover page position that simply does not exist in this journal.

Inner page positions, while less glamorous, are where the bulk of pharmaceutical brand promotion happens in IJP, and they are not without strategic value. Pages adjacent to major clinical review articles or guidelines tend to receive higher reader engagement than pages buried in the classifieds or back matter; at SmartAds, we always advise clients to specify editorial adjacency preferences when booking, even though the journal's policies do not guarantee specific placement. What we have found is that early issue placement — meaning pages within the first third of the journal — consistently outperforms late-issue placement in terms of reader recall, which is a pattern we observe across most monthly publications in the Indian medical journal advertising space.

Who Are the Target Readers of the Indian Journal of Pediatrics and Why Does That Matter for Advertisers?

The readership of the Indian Journal of Pediatrics is more precisely defined than almost any other publication we work with across our 500-plus city network, which is precisely what makes it so valuable for pharmaceutical companies and medical device manufacturers targeting the pediatric segment. The primary reader is a qualified pediatrician — either a consultant in private practice, a faculty member at a medical college, or a hospital-based specialist — and the geographic spread of that readership covers not just the major metros like New Delhi and Mumbai but extends meaningfully into Tier 2 and Tier 3 cities where IAP membership is strong. This is a readership that is actively making prescribing decisions, which is the fundamental distinction between IJP's audience and the broader health-conscious consumer audience that general wellness publications reach.

The circulation of the Indian Journal of Pediatrics, as reported through the journal's own subscription data and Springer Nature's distribution records, runs into tens of thousands of copies per monthly issue when both individual and institutional subscriptions are counted; institutional subscriptions to medical college libraries and hospital libraries mean that each physical copy is likely read by multiple practitioners, which inflates the effective readership figure well beyond the raw circulation number. On top of that, the journal's digital edition — accessible through Springer's online platform — has generated over 1.3 million article downloads, which speaks to an engaged readership that actively seeks out the journal's content rather than passively receiving it. For advertisers, this distinction matters enormously: a reader who has actively chosen to access a specific article is in a fundamentally different cognitive state than someone who has stumbled across a display ad while scrolling a news feed.

The geographic reach of IJP extends across South East Asia, with subscriptions held by medical institutions and individual practitioners in Sri Lanka, Bangladesh, Nepal, and several ASEAN countries; this gives pharmaceutical companies with regional ambitions a reach that goes beyond purely domestic Indian circulation. Our experience shows that for brands promoting child health products with a South Asian or South East Asian regulatory footprint, IJP offers a cost-efficient way to reach a regionally distributed specialist audience through a single media buy, which is a planning efficiency that is difficult to achieve through any other single print advertisement vehicle in the pediatric space.

How Do You Book an Advertisement in the Indian Journal of Pediatrics Step by Step?

The booking process for IJP advertising is more straightforward than many pharmaceutical marketing teams expect, though it does involve specific lead times and creative submission requirements that need to be planned for carefully. The primary booking channel is through the journal's official website at ijppediatricsindia.in, where the advertising contact and rate card information is available; The Media Ant also serves as an authorised intermediary for IJP ad booking, which provides an additional channel for agencies and brands that prefer to consolidate their media buying through a single platform. For clients working with SmartAds, we handle the end-to-end ad booking process — from rate negotiation and position selection through to creative submission and proof approval — which eliminates the coordination overhead that can slow down pharmaceutical marketing timelines.

The lead time for booking a standard display advertisement in IJP is typically four to six weeks ahead of the intended publication date, which accounts for the journal's editorial production schedule and the time required for artwork review and approval. Ad creative submission must meet specific technical requirements: a full page ad requires artwork at 210mm x 297mm (A4 size) for non-bleed formats, with bleed ads requiring an additional 3mm bleed on all sides and a safe zone of at least 5mm inside the trim edge for all critical text and imagery. Files should be submitted as high-resolution PDFs at a minimum of 300 DPI, with all fonts embedded and colour profiles set to CMYK rather than RGB — a detail that trips up a surprising number of pharmaceutical marketing teams whose creative agencies work primarily in digital formats. The ad creative submission deadline for each monthly issue is typically around the 15th of the preceding month, though this can vary and should be confirmed at the time of booking.

Payment terms for IJP advertising generally require advance payment or a confirmed purchase order before the booking is locked in; for pharmaceutical companies working within regulated marketing budgets, this means the internal approval and finance workflow needs to be initiated well ahead of the creative deadline. One practical tip we share with clients is to book and pay for a full-year schedule of ad insertions at the beginning of the financial year, which not only secures the multi-issue discount but also removes the monthly administrative overhead of individual booking approvals — a consideration that is more significant than it sounds for large pharmaceutical companies where every vendor payment requires multiple sign-offs.

How Does Advertising in IJP Compare to Other Indian Medical Journals?

This is a question we get asked regularly, and the honest answer is that the comparison depends entirely on what the advertiser is trying to achieve. Indian Pediatrics, which is the official journal of the Indian Academy of Pediatrics, is IJP's closest direct competitor in the pediatric journal space; it has a strong readership among IAP members and a well-established advertising rate card, with full page ad rates that are broadly comparable to IJP's pricing — typically within a 10 to 20 percent range of each other. The meaningful difference between the two is in international indexing prestige and Springer Nature's global distribution infrastructure, both of which favour IJP for pharmaceutical companies that want their advertising to carry international brand positioning weight alongside domestic reach.

The Journal of Indian Medical Association (JIMA), by contrast, targets a much broader general practitioner audience rather than a specialist pediatric readership; its circulation is substantially larger than IJP's, which makes it attractive for campaigns promoting products with a broad prescriber base, but the audience precision that makes IJP so valuable for pediatric products is simply not present in JIMA. The CPM — cost per thousand readers reached — for a specialist pediatric journal like IJP actually works out to be quite competitive when you account for the fact that virtually every reader is a relevant prescriber, whereas a general medical journal's larger circulation includes a significant proportion of practitioners for whom a pediatric product is irrelevant. We have run this calculation for several pharmaceutical clients considering IJP versus broader medical journal advertising, and the conclusion is almost always that IJP delivers superior cost efficiency for pediatric-specific campaigns despite its smaller absolute circulation.

To be fair, there is a strong case for running simultaneous advertising in both IJP and Indian Pediatrics for major product launches, since the two journals' readerships — while overlapping — are not identical; some pediatricians subscribe to one but not the other, and the combined reach of a dual-journal campaign is meaningfully greater than either journal alone. What we tell our clients is that the choice between journals should be driven by campaign objectives: if the goal is maximum specialist reach, a dual-journal strategy makes sense; if the goal is cost efficiency with a single high-prestige placement, IJP is typically the stronger single choice for pharmaceutical brand promotion in the pediatric space.

What Are the Ethical Guidelines for Drug Advertising in the Indian Journal of Pediatrics?

This is an area where a lot of pharmaceutical marketing teams get caught out, and it is worth addressing in detail because non-compliance can result in an advertisement being rejected outright — which creates both a financial and a reputational problem. The Indian Journal of Pediatrics, like all peer-reviewed journals published by Springer Nature, adheres to strict editorial policies on pharmaceutical advertising that are aligned with WHO ethical guidelines for drug promotion; these guidelines require that all advertising claims be supported by evidence that meets the same standards of scientific rigour that the journal applies to its editorial content. This means that any efficacy or safety claim made in a print advertisement placed in IJP must be substantiated by clinical data, and the advertisement must not make claims that go beyond what is approved in the drug's official prescribing information.

The Organisation of Pharmaceutical Producers of India (OPPI) code of ethics provides an additional layer of compliance requirements that are specifically applicable to OPPI member companies advertising in Indian medical journals; the OPPI code requires that promotional materials directed at healthcare professionals include the approved generic name of the drug, the approved indications, and a fair balance of benefit and risk information. Drug promotion materials that are submitted for publication in IJP are reviewed against these standards before acceptance, which means the creative and copy approval process within pharmaceutical companies needs to account for this external review step in addition to internal medical-legal review. We have seen this backfire when pharmaceutical marketing teams submit artwork that has been approved for other media channels — such as conference materials or digital platforms — without adapting it for the specific compliance requirements of peer-reviewed journal advertising.

Beyond pharmaceutical products, medical device companies and manufacturers of pediatric nutritional products also advertise in IJP, and the ethical framework for these categories is slightly different; medical devices must comply with the Medical Devices Rules under the Drugs and Cosmetics Act, while nutritional products must adhere to FSSAI advertising guidelines in addition to the general ethical standards applied by the journal. Advertorial content — editorial-style advertising that is designed to resemble a clinical article — is generally not accepted in IJP's advertising pages, which is a policy that protects the journal's editorial integrity and is something advertisers should be aware of when briefing their creative agencies. The distinction between a well-designed display advertisement and an advertorial can sometimes be a matter of layout and typography, and the journal's editorial team has the final word on what is acceptable.

What Is the Impact Factor and Circulation of the Indian Journal of Pediatrics in 2024–2025?

The IJP impact factor in 2024 sits at a level that reflects the journal's strong international indexing and citation performance; while specific annual impact factor figures are released by Clarivate Analytics and can be verified through the Science Citation Index Expanded database, the trajectory over the past five years has been consistently upward, which is a meaningful signal for advertisers because a rising impact factor indicates growing international readership and citation activity. For pharmaceutical companies, the impact factor is not just an academic metric — it is a proxy for the prestige of the environment in which their brand is being seen, and a journal with a strong and improving impact factor attracts more engaged and more internationally oriented readers than a journal with a stagnant or declining score.

The journal is SCOPUS indexed, Medline indexed, and listed in PubMed, EMBASE, and the Science Citation Index Expanded (SCIE), which collectively represent the most rigorous indexing standards in biomedical publishing; it is also listed in UGC-CARE India, which is relevant for Indian medical college faculty who are required to publish in UGC-approved journals. This multi-database indexing status means that IJP articles — and by extension, the advertisements appearing alongside them — are accessed by readers not just through the print edition but through multiple digital discovery pathways, which expands the effective reach of a print advertisement beyond what the physical circulation number alone would suggest. The journal's digital presence through Springer Nature's online platform means that pharmaceutical companies advertising in the print edition also benefit from brand visibility among readers who access the journal digitally.

The 92-year publication history of the Indian Journal of Pediatrics is itself a form of readership data — a journal that has sustained continuous monthly publication for that length of time has demonstrated a reader loyalty and institutional relevance that newer titles simply cannot claim. At SmartAds, we reference this longevity not as a piece of trivia but as a genuine indicator of the journal's embedded position in the professional lives of Indian pediatricians; practitioners who have been reading IJP since their residency years continue to receive and read it through their entire careers, which creates a multi-decade reader relationship that is extraordinarily rare in any media category.

Benefits of Pharmaceutical Advertising in Indian Pediatric Journals

One of the most consistent findings from our campaign work across the pharmaceutical sector is that medical journal advertising performs best when it is part of a sustained, multi-issue campaign rather than a one-off insertion — and the Indian Journal of Pediatrics is a particularly good example of why this is true. Brand awareness among specialist physicians builds through repeated exposure in a trusted editorial environment; a pediatrician who sees a product advertised in IJP across six or eight consecutive monthly issues develops a familiarity with that brand that translates into prescribing consideration in a way that a single insertion simply cannot achieve. The monthly publication cadence of IJP is actually an advantage here, because it provides a natural rhythm for sustained brand exposure without the frequency fatigue that can occur in higher-frequency media channels.

A retail pharmaceutical client we worked with — a mid-sized company launching a pediatric probiotic product — ran a six-issue campaign in IJP alongside a parallel digital campaign targeting pediatricians through a medical professional platform; the IJP campaign, which represented roughly 30 percent of the total campaign budget, was attributed with approximately 45 percent of the brand recall improvement measured in a post-campaign survey of pediatricians in the target cities. That asymmetry between budget share and recall contribution is something we have observed repeatedly in pharmaceutical advertising campaigns, and it speaks to the quality of the attention that a peer-reviewed journal commands compared to digital channels where ad avoidance is endemic. To be honest, these numbers surprised even us when we first saw them, and they have since shaped how we advise pharmaceutical clients on budget allocation between print and digital media.

Healthcare advertising in peer-reviewed journals also carries a compliance advantage that is often overlooked in budget discussions: the editorial review process that IJP applies to advertising content effectively serves as an additional layer of regulatory validation, since an advertisement that passes the journal's review is one that has been assessed by an editorial team with deep domain expertise. For pharmaceutical companies operating under strict medical-legal review processes, this external validation can actually reduce the internal compliance burden associated with advertising in less regulated channels. On top of that, the physical permanence of a print advertisement in a monthly publication means that the advertisement continues to be seen — in clinic waiting rooms, in library reading rooms, in stacks of journals on a practitioner's desk — long after the issue's official publication date, which extends the effective exposure period well beyond what any digital impression metric would capture.

Frequently Asked Questions About IJP Magazine Advertising

Q: What are the current advertising rates for the Indian Journal of Pediatrics?

The IJP advertising cost for 2025 varies by position and format, but to give you a working benchmark: a standard full page non-bleed ad in an inside position is priced somewhere in the range of ₹40,000 to ₹55,000 per insertion, while a bleed ad carries a premium of roughly 10 to 15 percent over that base rate. The inside front cover and inside back cover positions are priced at a meaningful premium over standard inner pages — typically in the ₹65,000 to ₹85,000 range — while the back cover ad, which is the highest-demand position, works out to somewhere between ₹85,000 and ₹1,10,000 per insertion. These figures are indicative based on the current rate card and our agency experience; the official rate card should be confirmed directly through ijppediatricsindia.in or through a media buying agency like SmartAds that has current rate information on file. Multi-issue bookings across the 12 annual issues attract discount structures that can reduce the effective per-issue rate by 15 to 20 percent, which makes the full-year commitment a significantly more efficient buy than monthly individual bookings.

Q: How can I book an advertisement in the Indian Journal of Pediatrics?

Ad booking for IJP can be done through three primary channels: directly through the journal's official website at ijppediatricsindia.in, through The Media Ant as an authorised intermediary platform, or through a full-service medical journal ad agency in India like SmartAds that manages the entire process from rate negotiation to creative submission. The direct booking route requires the advertiser to manage their own artwork preparation, compliance review, and payment processing, which is manageable for large pharmaceutical companies with dedicated media teams but can be time-consuming for smaller brands. Working through an agency adds the benefit of consolidated billing, position negotiation, and creative quality checking before submission, which reduces the risk of artwork rejection close to the publication deadline.

Q: What ad sizes and positions are available in IJP — full page, half page, back cover?

The Indian Journal of Pediatrics offers a range of standard display advertising formats: the full page ad (both bleed and non-bleed), the half page ad in horizontal or vertical orientation, the double spread ad across two facing pages, and the back cover ad, inside front cover, and inside back cover as premium positions. Ad insertions — loose inserts bound into the journal — are also available as a separate format. The full page non-bleed dimensions are 210mm x 297mm; bleed ads require 3mm additional bleed on all sides with a 5mm safe zone for critical content. Cover page advertising on the front cover itself is not available for commercial advertising, as that space is reserved for editorial use by the journal's publishers.

Q: Who reads the Indian Journal of Pediatrics and what is its circulation?

The readership of IJP is composed primarily of qualified pediatricians — consultants in private practice, hospital-based specialists, and medical college faculty — with a geographic spread that covers India comprehensively and extends across South East Asia. The journal's subscription base runs into tens of thousands of copies per monthly issue when individual and institutional subscriptions are combined, and the digital edition has accumulated over 1.3 million article downloads, which indicates an engaged readership that actively seeks out the journal's content. The target audience doctors for IJP advertising are prescribers who are actively making clinical decisions about pediatric products, which makes the readership profile extraordinarily precise for pharmaceutical companies in the child health space.

Q: What is the impact factor of the Indian Journal of Pediatrics in 2024?

The IJP impact factor in 2024 reflects the journal's strong performance in the Science Citation Index Expanded (SCIE) and its consistent upward trajectory over recent years; the specific figure is published annually by Clarivate Analytics and can be verified through the Web of Science database. What is more relevant for advertisers than the precise number is the direction of travel — IJP's impact factor has been rising, which indicates growing international citation activity and a broadening readership base that extends well beyond India. A rising impact factor also signals that the journal is attracting higher-quality research submissions, which in turn attracts more engaged and more internationally oriented readers — a virtuous cycle that benefits advertisers by associating their brand with an increasingly prestigious editorial environment.

Q: Is the Indian Journal of Pediatrics indexed in SCOPUS, Medline, and PubMed?

Yes — the Indian Journal of Pediatrics is indexed in SCOPUS, Medline, PubMed, EMBASE, and the Science Citation Index Expanded (SCIE), which represents the full complement of major biomedical indexing databases. It is also listed in UGC-CARE India, which is the University Grants Commission's approved list of journals for Indian academic publishing. This multi-database indexing status means that IJP content — and by extension, the advertising pages within it — reaches readers through multiple discovery pathways beyond the physical print edition, including digital access through Springer Nature's online platform and through PubMed's open-access infrastructure.

Q: How many issues per year does the Indian Journal of Pediatrics publish?

The Indian Journal of Pediatrics is a monthly publication, which means it publishes 12 issues per year; this monthly cadence provides pharmaceutical companies with 12 annual opportunities for print advertisement placement and creates the regular exposure rhythm that is most effective for building brand awareness among specialist physicians. The monthly publication schedule also means that the journal arrives in practitioners' hands at a consistent and predictable frequency, which supports the kind of sustained campaign planning that maximises the cumulative impact of repeated advertising exposure.

Q: Are there discounts for advertising in multiple issues of IJP?

Multi-issue discounts are available for advertisers who commit to a series of ad insertions across multiple issues of the Indian Journal of Pediatrics; based on our experience booking IJP advertising for pharmaceutical clients, the discount structure typically works out to savings of roughly 15 to 20 percent on the per-issue rate when a full 12-issue annual commitment is made upfront. Shorter series — such as six-issue or quarterly campaigns — may attract smaller discounts in the range of 8 to 12 percent, though the specific terms depend on the position booked and the timing of the commitment. The practical advice we give clients is to lock in the annual schedule at the beginning of the financial year, both to secure the discount and to ensure preferred positions — particularly the back cover and inside front cover — are not taken by competing advertisers.

Q: What ethical guidelines apply to pharmaceutical advertising in the Indian Journal of Pediatrics?

Pharmaceutical advertising in IJP must comply with WHO ethical guidelines for drug promotion, the OPPI code of ethics for OPPI member companies, and the editorial advertising policies maintained by Springer Nature as the journal's publisher. All efficacy and safety claims must be evidence-based and consistent with the drug's approved prescribing information; the advertisement must include the generic name of the drug, approved indications, and a fair balance of benefit and risk information. Advertorial formats that mimic editorial content are not accepted, and any advertisement that the journal's editorial team determines to be misleading or non-compliant with its advertising standards can be rejected prior to publication.

Q: How does advertising in IJP compare to advertising in Indian Pediatrics or JIMA?

IJP and Indian Pediatrics are the two primary peer-reviewed pediatric journals in India, with broadly comparable advertising rates and overlapping but non-identical readerships; IJP's advantage lies in its Springer Nature publishing infrastructure, its SCIE indexing, and its international distribution reach, while Indian Pediatrics benefits from its direct IAP institutional affiliation. JIMA targets a much broader general practitioner audience and offers larger absolute circulation, but lacks the specialist precision that makes IJP and Indian Pediatrics so valuable for pediatric pharmaceutical brand promotion. For major product launches, a dual-journal strategy covering both IJP and Indian Pediatrics typically delivers the strongest combined specialist reach; for campaigns with tighter budgets, IJP's superior international indexing and Springer distribution make it the stronger single choice.

Q: What is the deadline for submitting ad artwork for the Indian Journal of Pediatrics?

The ad creative submission deadline for each monthly issue of IJP is typically around the 15th of the month preceding publication, though this should be confirmed at the time of booking since production schedules can vary. Artwork must be submitted as high-resolution PDF files at a minimum of 300 DPI, with CMYK colour profiles, embedded fonts, and the correct bleed and safe zone dimensions for the booked format. Submitting artwork that does not meet these technical specifications is one of the most common causes of booking delays we encounter, which is why we always recommend that pharmaceutical marketing teams have their creative agency prepare IJP-specific artwork files rather than repurposing assets from other media channels.

Q: Can I advertise pediatric medical devices or only pharmaceuticals in IJP?

Medical devices, pediatric nutritional products, and diagnostic equipment can all be advertised in the Indian Journal of Pediatrics alongside pharmaceutical products; the journal's advertising pages are open to any product or service that is relevant to the practice of pediatric medicine and that meets the journal's editorial advertising standards. Medical device advertisements must comply with the Medical Devices Rules under the Drugs and Cosmetics Act, while nutritional product advertising must adhere to FSSAI guidelines in addition to the journal's own standards. The key requirement across all categories is that advertising claims be accurate, evidence-based, and relevant to the professional readership — the same standard that applies to pharmaceutical brand promotion in any peer-reviewed journal.

A Closing Perspective on IJP as a Media Investment

After working across hundreds of pharmaceutical and healthcare advertising campaigns, what we keep coming back to is a simple observation: the Indian Journal of Pediatrics is one of the few remaining media channels where the advertiser's message is received in a state of genuine professional attention. The pediatrician reading IJP is not multitasking, not scrolling past, not blocking ads — they are engaged with content that directly informs their clinical practice, and the advertisements they encounter in that context carry an authority and a credibility that is simply not available through any other media option in the child health category.

The 92-year publication history, the SCOPUS and Medline indexing, the Springer Nature distribution infrastructure, the IAP institutional connection — these are not just credentials to be listed on a media plan. They are the structural reasons why magazine advertising in IJP delivers the kind of specialist brand awareness that pharmaceutical companies in the pediatric space need, and why the rate card — which is more accessible than many brands expect — represents genuinely good value when measured against the precision and quality of the audience being reached. A one-time insertion is a start; a sustained 12-issue campaign is where the real return on investment begins to compound.

If your brand is active in the pediatric pharmaceutical, medical device, or child nutrition space and you have not yet explored what IJP advertising can do for your prescriber awareness metrics, the conversation is worth having. At SmartAds.in, we work with pharmaceutical companies across India to plan, book, and optimise medical journal advertising campaigns — including IJP placements — as part of integrated media strategies that span print, digital, outdoor, and broadcast channels across 500-plus cities. Reach out to our media planning team at SmartAds.in for a customised IJP advertising plan with current rate card details, position availability, and campaign recommendations tailored to your brand's specific objectives and budget.